Introduction
============

The reported incidence of acute respiratory distress syndrome (ARDS) ranges from 7 to 59 per 100,000 people \[[@B1],[@B2]\], and is associated with a mortality rate of 40 to 45%. This rate remains unacceptably high despite the introduction of lung protective ventilation and, although hospital mortality may be slowly decreasing, ICU and 28 day mortality have remained constant \[[@B1],[@B3]\]. Failure to implement lung protective ventilation (LPV) may be one of the reasons ICU mortality rates have remained unchanged \[[@B4]-[@B6]\]. When surveyed, health care providers reported that hypercapnia or its related effects were significant barriers to achieving LPV \[[@B7]\]. Hypercapnia complicated 14% of patients in the large ARDS network on the use of LPV \[[@B8]\]. However, patients with a high risk of death were excluded. In a study of severe ARDS, where tidal volumes were adjusted to target a mean airway pressure less than 28 cmH~2~O, all patients experienced hypercapnia \[[@B9]\]. As evidence emerges that tidal volumes \<6 ml.kg^-1^might further reduce mortality \[[@B9],[@B10]\], alternative strategies to manage the inevitable hypercapnia must be considered.

Permissive hypercapnia is one approach, but it only improves mortality when patients are ventilated with high tidal volumes \[[@B8]\]. Such volumes should no longer be used since 6 ml.kg^-1^is superior to 12 ml.kg^-1^and \<4 ml.kg^-1^might be superior to 6 ml.kg^-1^\[[@B9]-[@B11]\]. Although hypercapnia might have beneficial effects on oxygen delivery and attenuation of inflammation \[[@B12]\], it also harms injured lung through immunosuppression and impaired pulmonary epithelial repair \[[@B13],[@B14]\]. Furthermore, hypercapnia perpetuates right heart failure \[[@B15]\] and is undesirable in patients with elevated intracranial pressure. An alternative strategy to manage hypercapnia is extracorporeal carbon dioxide removal (ECCOR), a technology pioneered four decades ago \[[@B16]\] but only recently readily accessible through commercialization of several novel devices. ECCOR therefore deserves a fresh look and this review aims to provide an overview of devices currently available and those that may be available in the near future.

ECCOR in principle
==================

ECCOR is designed to remove carbon dioxide (CO~2~) and, unlike extracorporeal membrane oxygen (ECMO), does not provide significant oxygenation. A discussion of ECMO is beyond the scope of this article but is well reviewed elsewhere \[[@B17],[@B18]\]. In its simplest form, ECCOR consists of a drainage cannula placed in a large central vein, a pump, a membrane lung and a return cannula (Figure [1](#F1){ref-type="fig"}). Blood is pumped through the membrane \'lung\' and CO~2~is removed by diffusion. Membrane lungs are permeable to gases but not liquids. A flow of gas containing little or no CO~2~runs along the other side of the membrane, ensuring the diffusion gradient favors CO~2~removal.

![**Diagram demonstrating essential components of an extracorporeal carbon dioxide removal circuit**.](cc11356-1){#F1}

In contrast to ECMO, where the need for oxygenation requires high blood flow rates, ECCOR allows much lower blood flow rates, a result of major differences in CO~2~and oxygen (O~2~) kinetics. First, almost all the O~2~in blood is carried by hemoglobin, which displays sigmoidal saturation kinetics. Assuming normal hemoglobin and venous O~2~, each liter of venous blood can only carry an extra 40 to 60 ml of O~2~before the hemoglobin is saturated. Blood flows of 5 to 7 L.minute^-1^are therefore required to supply enough O~2~for an average adult (250 ml. minute^-1^). Conversely, most CO~2~is transported as dissolved bicarbonate, displaying linear kinetics without saturation. Thus, 1 L of blood is capable of carrying more CO~2~than O~2~, and 250 ml of CO~2~can be removed from \<1 L of blood. Second, CO~2~diffuses more readily than O~2~across extracorporeal membranes because of greater solubility \[[@B17]\].

The membrane lung
-----------------

The membrane lung made long-term extracorporeal gas exchange feasible. Before membrane lungs, extracorporeal circuits achieved gas exchange by creating a direct air-blood interface, either bubbling air through blood or creating a thin film of blood on the surface of a rotating cylinder/disc. However, blood-air interfaces denature proteins, activate clotting and inflammatory pathways, and damage circulating cells \[[@B19]\]. Consequently, devices relying on blood-air interfaces cannot be used more than a few hours without serious complications.

The concept of placing a barrier between blood and air began with the observation that gas exchange occurred across cellophane tubing in hemodialysis machines \[[@B20]\]. This led to the development of membrane lungs consisting of gas permeable silicone-rubber mounted on a nylon mesh \[[@B21]\]. The nylon mesh provided structural strength and decreased leakage from random pinhole defects, which occur during the manufacture of thin silicone-rubber membranes \[[@B19]\]. Three major factors determine the amount of gas crossing membranes: the diffusion gradient, the membrane-blood contact time and the membrane diffusion characteristics.

The CO~2~diffusion gradient is determined by the CO~2~content of the blood and the air passing through the membrane lung, as well as the speed of the airflow. Membrane-blood contact time is determined by membrane geometry. In early devices, Theodore Kolobow arranged the membrane into a coil \[[@B22]\] and used a fabric with an irregular surface, increasing the surface area \[[@B23]\]. Hollow fiber membranes have now replaced coiled silicon-rubber membranes. Early fibers were constructed with microporous polypropylene. Micropores create microscopic blood-gas interfaces allowing efficient gas exchange, but also cause plasma leak. Recently, nonmicroporous poly-4-methyl-1-pentene (PMP) has been used; it provides superior gas exchange, better biocompatibility and is less susceptible to plasma leak \[[@B24]-[@B26]\]. Adding covalently bound heparin to membrane surfaces enhances biocompatibility, and gas exchange has been improved by arranging fibers into a complex mat and running blood on the outside \[[@B27]\] (Figure [2](#F2){ref-type="fig"}). This arrangement allows perpendicular blood flow to the fibers, improving mass transfer by reducing the diffusion path length compared to parallel flow. Modern membrane lungs achieve adequate gas exchange with surface areas of 1 to 3 m^2^(Table [1](#T1){ref-type="table"}).

![**Diagram showing the basic principle of a membrane lung**. Sweep gas passes through the hollow fibres. Hollow fibers are arranged in a complex mat. Image courtesy of Medos Medizintechnik AG (Stolberg, Germany).](cc11356-2){#F2}

###### 

Extracorporeal carbon dioxide removal circuit components

  Component       Name                      Special features                                                           Manufacturer
  --------------- ------------------------- -------------------------------------------------------------------------- --------------------------------------------
  Pump            Centrimag                 Impeller elevated in electromagnetic field                                 Levotronix LLC Waltham, MA, USA
                  RotaFlow                  Impeller driven by electromagnetic field and has single sapphire bearing   Maquet, Rastatt, Germany
                  Biomedicus                Impeller drive shaft supported by sealed bearings                          Medtronic, Eden Praire, MN, USA
                  Deltastream               Diagonally streamed impeller, sealed bearings                              Medos Medizintechnik AG, Stolberg, Germany
  Membrane lung   Quadrox D                 1.8 m^2^surface area, 250 ml priming volume                                Maquet, Rastatt, Germany
                  iLA membrane ventilator   1.3 m^2^surface area, 175 ml priming volume                                Novalung GmbH, Heilbronn, Germany
                  hilite 7000LT             1.9 m^3^surface area, 275 ml priming volume                                Medos Medizintechnik AG, Stolberg, Germany
                  Affinity NT               2.5 m^2^surface area, 270 ml priming volume                                Medtronic, Eden Praire, MN, USA

This list is not exhaustive, but demonstrates the range of products available. iLA, interventional lung assist.

The pump
--------

Blood flow through ECCOR circuits can be achieved in one of two ways. In patients with sufficient arterial pressure, a pumpless system can be used where blood is driven out of an arterial cannula by high arterial pressures and returned through a venous cannula, often called arteriovenous CO~2~removal (AVCO2R). Pumpless systems result in less blood trauma, but require large bore arterial cannulas and an adequate cardiac output. The alternative is to use a mechanical pump.

Early devices used roller or peristaltic pumps. Although cheap and reliable, these pumps were prone to blood trauma - for example, hemolysis - from compression and heating of blood components. Blood trauma is less of a problem at lower blood flow rates - for example, those used in dialysis. The introduction of rotary pumps has resulted in simpler yet effective systems that cause less blood trauma. Two main types of rotary pumps are used in ECCOR devices, centrifugal and diagonal flow pumps.

Centrifugal pumps use a radial rotating impeller to create a suction vortex that draws blood into the center of the pump and spins it outwards, imparting centrifugal momentum, which is converted into driving pressure. In diagonal flow pumps, impellor design is a mix of radial and axial geometry. Centrifugal pumps tend to generate high pressures and low flows, whereas diagonal pumps produce both high flows and high pressures \[[@B28]\]. Impellors are connected to a drive shaft, requiring bearings to support the rotational movement. Exposure of blood to typical bearings promotes clotting, causing deposition of coagulation debris that can seize the bearing. Some pumps use seals to protect the bearings, but these can wear out; other designs use biocompatible materials to construct the bearings. In the most advanced centrifugal pumps impellors are completely suspended in an electromagnetic field, eliminating the need for a drive shaft or bearings and reducing heating, minimizing blood trauma and lowering the incidence of mechanical failure.

Access cannula
--------------

Early clinical trials placed separate drainage and return cannulas in the saphenous veins \[[@B29],[@B30]\]. Modern cannulas are placed percutaneously in a femoral-femoral or femoral-jugular orientation. To maintain flow and minimize blood trauma, heparin-coated wire-reinforced cannulas are used. Recently, a high flow, wire-reinforced double-lumen catheter has been developed. It is placed via the right internal jugular vein and the drainage port (tip of the cannula) is advanced into the intra-hepatic inferior vena cava using ultrasound guidance \[[@B31]\]. In this orientation the return port aligns with the right atrium, minimizing recirculation. New ECCOR devices with flow rates comparable to those in dialysis use double-lumen cannulas similar to dialysis catheters \[[@B32],[@B33]\].

ECCOR in practice
=================

The first clinical trial of extracorporeal respiratory support was published in 1979, and used the Kolobow spiral-coil membrane lung, a roller pump and venoarterial access to provide ECMO \[[@B34]\]. This trial found no difference between conventional treatment and ECMO. At about the same time Gattinoni and coworkers introduced ECCOR \[[@B35]\], but did not publish the first clinical trial until 1986, where patients with severe ARDS were selected for LPV combined with ECCOR (Kolobow spiral-coil membrane lung, and a roller pump). Observed mortality was 51% using this technique \[[@B29]\]. Subsequent work was initially encouraging \[[@B36]\] but a randomized controlled study in 1994 concluded that ECCOR conferred no survival advantage \[[@B30]\]. Importantly, complication rates were high with ECCOR, being discontinued in 33% of cases owing to bleeding, and 20% experiencing circuit clotting. Recently, new devices with lower complication rates have demonstrated improved survival when combined with ultra-protective ventilation \[[@B9]\]; some are already available whilst others are in advanced development. They can be broadly categorized into i) arteriovenous devices, ii) venovenous devices, iii) gas exchange catheters and iv) respiratory dialysis.

Arteriovenous carbon dioxide removal
====================================

AVCO2R is commercially available through Novalung (GmbH, Hechingen, Germany) and marketed as the interventional lung assist (iLA) membrane ventilator (Figure [3](#F3){ref-type="fig"}). The membrane lung, frequently called the \'Novalung\', utilizes a low resistance design allowing blood flow using the patient\'s own arteriovenous pressure gradient. Cannulas are placed percutaneously in the femoral artery and vein \[[@B37],[@B38]\]. A similar system has been developed in the United States using the Affinity NT (Medtronic, Minneapolis, MN) \[[@B39],[@B40]\].

![**Image of the interventional lung assist (iLA), blood is propelled through the circuit by arterial pressure**. Image courtesy of Novolung (GmbH, Hechingen, Germany).](cc11356-3){#F3}

Pumpless systems require an arteriovenous pressure gradient ≥60 mmHg, which is unsuitable for hemodynamically unstable patients. Further, cannulation of a major artery can result in distal ischemia \[[@B37]\], although measuring the artery diameter with ultrasound and selecting a cannula that occupies no more than 70% of the lumen reduces this risk \[[@B38]\]. AVCO2R has been successfully used to facilitate LPV in patients with ARDS \[[@B41]-[@B43]\], severe asthma \[[@B44]\] and as a bridge to lung transplantation \[[@B45]\].

Venovenous carbon dioxide removal
=================================

Venovenous carbon dioxide removal (VVCO2R) requires a mechanical pump to propel blood through the circuit and can be broadly divided depending on whether the pump and membrane lung are separate components or incorporated into a single console. When separate components are used, the circuit is set up as described in Figure [1](#F1){ref-type="fig"}. Table [1](#T1){ref-type="table"} shows some of the different components that can be used. These circuits are more complicated to operate, often need flow rates \>1 L.minute^-1^and may need multidisciplinary support. The growth of programs in more general settings has provided impetus to simplify ECCOR, resulting in several devices where the pump and membrane lung are combined into one console.

iLA Activve
-----------

The iLA Activve mounts the Novalung and a diagonal flow pump together in one device. At higher blood flow rates this device can provide venovenous ECMO. Conceptually, this is the simplest method of providing ECCOR via a console, and although it does not provide any special benefits over separate components, the pump is designed to provide reliable flows throughout a large range of flow rates.

Decap/Decapsmart
----------------

The Decap system (Hemodec, Salerno, Italy) uses a membrane lung in series with a hemodialysis filter and roller pump (Figure [4](#F4){ref-type="fig"}). The hemodialysis filter serves two purposes with regard to CO~2~removal. First, it reduces the chance of bubble formation by increasing resistance within the membrane lung. Second, ultrafiltrate from the filter is returned to the blood stream prior to the membrane lung inflow. Since ultrafiltrate contains dissolved CO~2~, recirculating in this way allows additional CO~2~removal by creating a greater flow rate through the membrane lung than the flow from the patient. Consequently, smaller membrane lungs can be used (0.3 to 1.35 m^2^) with lower flow rates (\<500 ml.minute^-1^) than conventional ECCOR \[[@B33]\], resulting in similar anticoagulation requirements to continuous venovenous hemodialysis \[[@B46]\]. The Decap has been successfully used in adults and children \[[@B9],[@B47],[@B48]\].

![**Diagram showing the basic circuit design of the Decap (Hemodec, Salerno, Italy)**. Blood is pumped through a membrane lung in series with a dialysis filter, and ultrafiltrate is returned to the blood prior to the membrane. UF, ultrafiltrate.](cc11356-4){#F4}

Hemolung
--------

The Hemolung (Alung Technologies, Pittsburgh, USA) is the latest device to enter the ECCOR arena. In this device the membrane lung and centrifugal pump are combined together, acting as one unit (Figure [5](#F5){ref-type="fig"}). Blood is drawn into the unit via a rotating impeller. The center contains a rotating core that accelerates blood towards a surrounding stationary fiber bundle. This is called active mixing; the rotating core generates disturbed blood flow patterns subjacent to the fiber membrane, reducing diffusional resistance and increasing gas exchange. As a result, CO~2~removal is more efficient and achieved with a smaller membrane surface area and flows of 400 to 600 ml.minute^-1^, which allows use of smaller double-lumen catheters. The smaller membrane surface area, siloxane coating for plasma resistance and covalently bound heparin result in lower anticoagulation requirements \[[@B32]\]. Gas flow through the membrane lung is supplied under negative pressure, a safety feature preventing air embolism if the membrane is disrupted. The Hemolung enabled a 50% reduction in minute ventilation in animal trials and was recently successfully used in a clinical case series of five adults \[[@B49]\].

![**Cross sectional diagram of Hemolung (Alung Technologies, Pittsburgh, USA) showing rotating core that accelerate blood to the surrounding fiber bundle**. Adjacent image shows the Hemolung console. Courtesy of Alung Technologies (Pittsburgh, USA).](cc11356-5){#F5}

Gas-exchange catheters
======================

Several gas-exchange catheters have been developed but only one, the intravenocaval oxygenator and carbon dioxide removal device (IVOX), has been used clinically. These devices package hollow fiber membrane lungs into a catheter that is small enough to be placed in the vena cava, that is, \<15 mm in diameter. Intracorporeal catheters are conceptually attractive because they are exposed to 2 to 3 L.minute^-1^of blood flow and therefore CO~2~removal is not flow limited.

The IVOX was designed for both oxygenation and CO~2~removal. Orienting \'crimped\' membrane fibers in a spiral arrangement maximized gas exchange by increasing surface area and creating disturbed blood flow patterns over the membrane \[[@B50]\]. Disturbed blood flow provides convection velocity towards the fiber surfaces, reducing diffusional resistance. The membrane surface of the IVOX ranged from 0.2 to 0.5 m^2^\[[@B51]\] and gas flow was applied under negative pressure; an important safety feature in intracorporeal devices since there is no other opportunity to prevent air embolism if the membrane is disrupted.

In animal trials the IVOX consistently removed 40 ml.minute^-1^of CO~2~, but oxygen delivery was less reliable. Clinical experience was mixed; the IVOX facilitated lower ventilator settings in some studies \[[@B52]\], but made no difference in others \[[@B53],[@B54]\]. On the whole, gas exchange was too limited and placement associated with high complication rates from bleeding and thrombosis \[[@B52]\]. Commercial development has subsequently ceased.

Future directions and devices in development
============================================

Several of the above devices are undergoing clinical trials, often in combination with LPV (Table [2](#T2){ref-type="table"}). Other promising approaches are still in development, in particular more efficient gas exchange catheters and respiratory dialysis. Novel methods to maximize CO~2~removal, such as blood acidification, are also under investigation \[[@B55]\].

###### 

Current active trials from clinicaltrials.gov accessed April 2012

  Study title                                                                                                                                               Device                                                                                                              Sponsor                         Status
  --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------- --------------------
  Extracorporeal CO~2~removal in COPD (DECOPD)                                                                                                              Decap Smart                                                                                                         University of Turin, Italy      Recruiting
  Pulmonary and Renal Support during Acute Respiratory Distress Syndrome (PARSA)                                                                            Neonatal membrane lung (HiLite 800 LT, Medos) within dialysis circuit (Multifiltrate kit 7, CVVH 1000, Fresenius)   Hopital Ambroise Pare, France   Recruiting
  Low-flow ECCO2-R and 4 ml/kg Tidal Volume vs. 6 ml/kg Tidal Volume to Enhance Protection From Ventilator Induced Lung Injury in Acute Lung Injury (ELP)   Not specified                                                                                                       University of Turin, Italy      Not yet recruiting

Gas-exchange catheters in development
-------------------------------------

Following the IVOX, attention has focused on developing a catheter that meets 50% of adult gas exchange requirement. Several ingenious approaches are being studied. The first approach is generation of active mixing within the catheter. This was initially attempted using an intraaortic balloon pump close to the shaft of the IVOX catheter \[[@B56]\]. However, the membrane fibers were not fixed and fiber movement opposed active mixing. The Hattler catheter solved this using a rigid fiber mat constructed around a central balloon \[[@B57]\] (Figure [6](#F6){ref-type="fig"}). Rapid pulsation of the balloon directed blood flow over the membrane fibers, causing active mixing. In this design membrane fibers do not occupy the whole lumen of the vein, causing less fiber drag on blood flow. In animal trials the Hattler catheter exchanged CO~2~at 305 ml.minute^-1^.m^-2^, almost double the IVOX rate at similar CO~2~concentrations \[[@B58],[@B59]\].

![**Diagram of the Hattler catheter showing the rigid hollow fiber bundle surrounding a pulsating ballon**.](cc11356-6){#F6}

Active mixing can also be achieved by rotating the fiber bundle; a strategy used in the dynamic intravascular lung assist device (D-ILAD) \[[@B60]\]. Although the D-ILAD was almost twice as efficient as balloon-pulsating catheters, rotating fibers could damage vessel walls upon contact. Recently, the Hattler catheter has been modified by replacing the balloon with a series of small impellers. It has been successfully used in animals and has CO~2~exchange rates similar to the D-ILAD \[[@B61]\].

Finally, in addition to active mixing, CO~2~exchange has been improved by covalent immobilization of carbonic anhydrase to the surface of the hollow fiber membrane \[[@B62]\]. As a result, CO~2~is more rapidly generated from bicarbonate, facilitating removal.

Respiratory dialysis
--------------------

In the 1980s, several groups reported the results of animal experiments using dialysis to remove CO~2~in the form of bicarbonate. This approach is appealing because CO~2~is transported in the form of bicarbonate, which moves freely across dialysis membranes. Conventional hemodialysis uses bicarbonate-containing dialysates to correct the metabolic acidosis accompanying renal failure, but bicarbonate-free dialysates can remove enough CO~2~to replace pulmonary ventilation in dog models \[[@B63]\]. Currently, respiratory dialysis is limited by the inability to maintain electrolyte concentrations and pH whilst removing bicarbonate. Several approaches to replace bicarbonate have been attempted using sodium hydroxide, tromethamine (THAM), and organic anions. However, fluid gain, hyperchloremic acidosis, hemolysis, cardiac arrhythmias and acid-base derangements have prevented successful long-term use \[[@B64],[@B65]\].

Recently, hemofiltration has been used to remove bicarbonate. One group used sodium hydroxide in a post-filter replacement fluid and maintained pH and CO~2~within physiological range for 18 hours in hypoventilated sheep. However, hyperchloremic acidosis developed and blood flow rates exceeding 500 ml.minute^-1^would be needed to remove sufficient CO~2~in humans \[[@B66]\]. Another group removed bicarbonate by using pre-filter replacement fluid containing THAM. Physiologic CO~2~levels and pH were maintained for 1.5 hours, but it was not determined whether THAM had the same long-term problems seen in the hemodialysis models \[[@B67]\]. Nonetheless, respiratory dialysis holds much promise if the problems of electrolyte and acid-base disturbances can be solved.

Conclusion
==========

Several modalities of providing ECCOR are now either available or in development. As evidence favoring low-volume, low-pressure ventilation in ARDS accumulates, the argument for applying these ventilation strategies in all critically ill patients will gather momentum. However, successful application is dependent upon a safe, reliable approach for CO~2~removal.

Simpler more efficient ECCOR devices requiring lower blood flow rates and smaller access cannulas promise to improve safety and ease of use. Novel designs, such as the Decap, can serve the dual purpose of renal support and ECCOR. However, other solutions currently in development, gas exchange catheters and respiratory dialysis, promise to be minimally invasive, easy to initiate and well tolerated. They may even eliminate the need for intubation in some forms of respiratory failure, where CO~2~is the primary problem \[[@B68]\]. Familiarity with devices already available can change our approach to ARDS and prime the ICU for the arrival of devices that may revolutionize our approach to respiratory failure.
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